Adverum Biotechnologies (ADVM, Financial) received a revised price target from Mizuho. Analyst Graig Suvannavejh has adjusted his price target for the company to $12.00, down from the previous target of $16.00. This change represents a 25% decrease.
Despite the adjustment in the price target, Mizuho maintains its 'Outperform' rating on Adverum Biotechnologies (ADVM, Financial). The rating remains unchanged from the prior 'Outperform' status.
These updates were reported on June 26, 2025, reflecting the analyst's latest assessment of the company's prospects.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for Adverum Biotechnologies Inc (ADVM, Financial) is $20.75 with a high estimate of $33.00 and a low estimate of $4.00. The average target implies an upside of 740.08% from the current price of $2.47. More detailed estimate data can be found on the Adverum Biotechnologies Inc (ADVM) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Adverum Biotechnologies Inc's (ADVM, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
